Verge Genomics announces a multi-institution collaboration with Columbia University, MGH, USC and the University of Michigan to advance ALS research


Justin Ichida (Photo by Cristy Lytal)

Verge Genomics, a drug discovery company utilizing genomic data for neuroscience therapeutics, announced today that it is has established a multi-institution industry-academic collaboration with four top universities focused on accelerating the translation of preclinical models of amyotrophic lateral sclerosis (ALS) through the creation of a comprehensive foundation of ALS data, encompassing genomic, biochemical, and phenotypic data. Collaborators include the Motor Neuron Center at Columbia University, Massachusetts General Institute for Neurodegenerative Disease, the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC, and the Department of Neurology at the University of Michigan Medical School.

To read more, visit